E. Krognes - Aug 19, 2021 Form 4 Insider Report for Denali Therapeutics Inc. (DNLI)

Role
CFO and Treasurer
Signature
/s/ Tyler Nielsen, by power of attorney
Stock symbol
DNLI
Transactions as of
Aug 19, 2021
Transactions value $
-$113,263
Form type
4
Date filed
8/23/2021, 08:24 PM
Previous filing
Nov 19, 2021
Next filing
Jan 5, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DNLI Common Stock Sale -$103K -2.09K -2.14% $49.52 95.5K Aug 19, 2021 Direct F1, F2, F3
transaction DNLI Common Stock Sale -$10K -200 -0.21% $50.07 95.3K Aug 19, 2021 Direct F1, F3, F4
holding DNLI Common Stock 850K Aug 19, 2021 See footnote F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units.
F2 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $49.00 to $49.96 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3 Includes 75,358 restricted stock units.
F4 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $50.04 to $50.09 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F5 The shares are held of record by The Steve Edward Krognes Revocable Trust U/A DTD 01/25/2016, for which the Reporting Person serves as trustee.